<DOC>
	<DOCNO>NCT00770978</DOCNO>
	<brief_summary>The purpose research study measure level ceftobiprole blood urine administration four dos ceftobiprole . Safety drug also evaluate .</brief_summary>
	<brief_title>Open Label Study Ceftobiprole Evaluate Pharmacokinetics Adults Hospitalized ICU</brief_title>
	<detailed_description>Patients receive intravenous dose ceftobiprole infuse 4 hour . Multiple blood sample obtain determine concentration ceftobiprole plasma . Pharmacokinetic parameter clearance volume distribution calculate . 1000mg every 8hours every 12 hour</detailed_description>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Informed Consent Between 18 75 year age inclusive BMI 18 35 inclusive Albumin &lt; 3.3 g/dL clinical evidence edema Negative Pregnancy test Expected survival least 7 day Known drug allergy ( include penicillin , cephalosporin , carbapenems , betalactams ) Renal impairment ( CrCl &lt; 50 mL/min ) dialysis History seizures ALT AST &gt; 5 time upper normal limit Sustained shock , unresponsive sympathomimetics Conditions may jeopardize adherence protocol ( NYHA Class 4 cardiac disease , &gt; 15 % total body burn significant third degree burn )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ICU</keyword>
</DOC>